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Abstract So far, the physiological role of insulin-like growth
factor binding protein-2 (IGFBP-2) has not been demonstrated
directly. Therefore, we transfected 293 cells with an expression
vector containing the CMV promoter and the complete cDNA of
mouse IGFBP-2. Secretion of bioactive IGFBP-2 into condi-
tioned medium was demonstrated by Western ligand and
Western immunoblotting and quantified by specific RIA. For
the analysis of cell proliferation three clones exhibiting either
high or low/no IGFBP-2 expression were selected and compared
to non-transfected parental 293 cells. IGFBP-2 secreting clones
displayed reduced conversion of thiazolyl blue when compared to
negative clones or non-transfected parental 293 cells (P60.01).
The lower growth activity measured in the IGFBP-2 secreting
clones was compensated in great part by the administration of
exogenous IGF-I or -II. Conditioned media of IGFBP-2
secreting clones inhibited growth of IGF-responsive colon tumor
cell lines (LS513, HT-29) while those of negative clones did not.
In addition, conditioned medium from a clone expressing high
levels of IGFBP-2 inhibited anchorage-independent growth of
LS513 and HT-29 cells. In contrast, growth of an IGF-
unresponsive tumor cell line (Co-115) was not affected by the
conditioned media. We hypothesize that IGFBP-2 might
sequester the IGFs and thus prevent them from transferring
their mitogenic signals.
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1. Introduction
Insulin-like growth factor binding protein-2 (IGFBP-2) is
the second most abundant IGF binding protein in serum
and binds IGF-II with several-fold higher a⁄nity than IGF-
I [1,2]. Increased serum levels of IGFBP-2 are found in asso-
ciation with fasting and a number of pathological syndromes,
including non-islet cell tumor hypoglycemia (NICTH),
chronic renal failure, liver cirrhosis and certain leukemias
[3]. However, it is not clear whether the increase in IGFBP-
2 levels plays a speci¢c role in the pathogenesis of these dis-
eases. Upregulation of IGFBP-2 expression after infusion of
IGF [4] and in patients su¡ering from IGF-II secreting tumors
[5] or in transgenic mice overexpressing IGF-II [6,7] suggested
a positive regulation of IGFBP-2 expression by increased lev-
els of free IGFs. IGFBP-2 might also play a major role in
reproductive tissues [8^10], where its decrease was correlated
with increased tumorigenicity [11].
Disruption of the IGFBP-2 gene in mice resulted in only
minor phenotypic changes, suggesting functional redundancy
of the IGFBPs [12,13]. However, recent ¢ndings in transgenic
mice [14] and rabbits [15] overexpressing des(1^3) IGF-I or
IGF-I locally in the mammary gland provided indirect evi-
dence of an inhibitory e¡ect of IGFBP-2 on IGF-I action.
While des(1^3) IGF-I inhibited involution of the mammary
gland and caused multiple pathological alterations in the
transgenic mouse model [14], these changes were absent in
transgenic rabbits in spite of extremely high levels of IGF-I
in their milk [15]. IGFBP-2 levels in milk were markedly in-
creased in both models; however, due to its reduced a⁄nity
for des(1^3) IGF-I, IGFBP-2 might have exerted a protective
e¡ect only in the IGF-I transgenic rabbits.
To evaluate the role of IGFBP-2 on IGF action in a de¢ned
in vitro system, we transfected 293 human embryonic kidney
¢broblasts with an IGFBP-2 expression vector and analyzed
cell proliferation of clones stably overexpressing IGFBP-2.
The mode of IGFBP-2 action was further investigated by
exposure of IGF-responsive and unresponsive colon carcino-
ma cell lines to media conditioned by the selected clones. We
show evidence that IGFBP-2 provides negative signals in sev-
eral cellular systems.
2. Materials and methods
2.1. Construction of pCMV-int-IGFBP-2
The EcoRI/NotI fragment (1450 bp) including full length mouse
IGFBP-2 complementary DNA [16], kindly donated by Dr. S.
Drop, Rotterdam, The Netherlands, was blunt ended and subcloned
into the SalI digested vector pGEM-4Z (Promega, Boehringer Ingel-
heim, Heidelberg, Germany). From the resulting subclone a 1480 bp
restriction fragment was subcloned into BglII/PstI digested mamma-
lian expression vector pCMV-int as described previously [17]. From
the resulting vector IGFBP-2 cDNA can be cut using EcoRI/PstI
digestion (Fig. 1).
2.2. Stable transfection of 293 human embryonic kidney ¢broblasts
Human embryonic kidney ¢broblasts (293 cells), obtained from
American Type Culture Collection (ATCC, Rockville, MD, USA),
were grown in Dulbecco’s modi¢ed Eagle’s medium (DMEM) with
10% fetal calf serum and subcultured every week at reduced splitting
rate (1/10). 293 cells were transfected using the DMRIE-C reagent
(Gibco BRL, Eggenstein, Germany). In brief, 293 cells were cultured
in Petri dishes (10 cm in diameter) to 60% con£uence and incubated
for 12 h in 3.5 ml transfection solution containing serum-free DMEM
medium, 8 Wg pCMV-int-mIGFBP-2 (XhoI linearized) and 0.8 Wg
EcoRI linearized neomycin resistance plasmid pSV2neo (Clontech,
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Heidelberg, Germany). Monolayers were washed once in serum-free
medium and kept in culture medium for 24 h. Positive clones were
selected by G418 (Gibco BRL; 250 Wg/ml) in the culture medium for
2 weeks. G418 was replaced every 2 days. Colonies were isolated from
the Petri dish and subcultured several times. Genomic DNA from
selected clones was isolated using Wizzard genomic DNA puri¢cation
system (Promega). 10 Wg of genomic DNA were EcoRI/PstI digested,
separated by 1% TAE agarose gel electrophoresis and blotted onto
Nytran membranes (Schleicher and Schuell, Dassel, Germany) by
capillary transfer. A £uorescein labeled riboprobe (riboprobe length:
1.5 kb) was synthesized using the Riboprobe Gemini Transcription
System (Promega) and £uorescein-12-UTP (Boehringer Mannheim,
Mannheim, Germany). The riboprobe was puri¢ed as described pre-
viously [18]. Hybridization and detection were carried out using the
£uorescein Gene Images labeling system (Amersham Buchler,
Braunschweig, Germany).
2.3. Analysis of mRNA expression
Cells were homogenized using a cell homogenizer (ART, Muºhlheim,
Germany) in 4 M guanidine thiocyanate, 25 mM sodium acetate and
0.835% mercaptoethanol for 25 s. RNA was pelleted in 5.7 M CsCl,
25 mM sodium acetate solution (20 h; 20‡C; 200 000Ug). The RNA
pellet was dissolved in DEPC-treated water and precipitated overnight
at 320‡C. The amount of RNA was calculated from the measured
absorbance at 260 nm. The ratio of the absorbances at 260 nm and
280 nm was routinely higher than 1.7. The quality and quantity of the
RNA was further examined by methylene blue staining of the North-
ern blots, where the bands of the 28S and 18S rRNA showed the
typical ratio, clear shape and equal intensities of bands from di¡erent
RNA samples.
For the analysis, 10 Wg of total RNA was separated by formalde-
hyde agarose gel electrophoresis according to standard protocols and
blotted onto nylon membranes by capillary transfer. For the hybrid-
ization a £uorescein labeled IGFBP-2 riboprobe was used as for
Southern blot hybridization. The Northern blots were exposed to
Biomax ¢lms (Sigma, Deisenhofen, Germany) for 2^100 min. The
molecular size of the respective mRNA transcripts was estimated by
comparison of their relative mobilities with an RNA size standard
(Gibco BRL).
2.4. Analysis of IGFBP-2 expression
Conditioned media (described below) were analyzed by Western
ligand blot analysis according to the method of Hossenlopp et al.
[19] with modi¢cations as previously described [6] to demonstrate
the capacity of the secreted mIGFBP-2 to bind human IGF-II.
Brie£y, media were diluted 1:5 with sample bu¡er (50 mM Na2HPO4,
pH 7.0; 1% (w/v) sodium dodecyl sulfate (SDS); 50% (w/v) glycerin),
boiled (5 min) and electrophoresed on a 5% stacking/12% separating
SDS-polyacrylamide gel using the Mini Protean II system (Bio-Rad,
Munich, Germany). Separated proteins were transferred to a nitro-
cellulose membrane (Millipore, Eschborn, Germany). The blots were
blocked with 1% ¢sh gelatin and incubated with [125I]IGF-II (106 cpm
per blot). Binding proteins were visualized on Phospho-Imager Storm
(Molecular Dynamics, Krefeld, Germany). All hybridization and
washing steps were performed at 4‡C.
IGFBP-2 in the conditioned media was identi¢ed by Western blot
analysis using a cross-reacting rabbit antiserum to human IGFBP-2
(kindly provided by Dr. M. Elmlinger, Universitaºts-Kinderklinik
Tuºbingen, Germany). This antiserum has successfully been used for
immunoprecipitation of mIGFBP-2 from mouse serum [18]. Mem-
branes were prepared as described above with the single exception
that the proteins were separated under reducing conditions, and in-
cubated with human IGFBP-2 antiserum (1/1000) for 1 h and with
peroxidase coupled anti-rabbit IgG antibody (Dianova, Hamburg,
Germany). Signals were generated using diaminobenzidine (Sigma).
IGFBP-2 levels in conditioned media were quanti¢ed by radioimmu-
noassay [3].
2.5. Preparation and evaluation of conditioned media
For preparation of conditioned media from selected pCMV-
IGFBP-2 transfected 293 cell clones, con£uent monolayers in 175
cm2 cell culture £asks (Greiner) were washed two times with phos-
phate bu¡ered saline (PBS) and incubated in 30 ml serum-free
DMEM for 24 h. Conditioned media were harvested, centrifuged
and stored aliquoted at 320‡C until further use. The conditioned
media were analyzed by use of di¡erent colon carcinoma cell lines
(HT-29, LS513 and Co-115). Colon carcinoma cells were maintained
in DMEM/F12 containing 5% FCS. For the proliferation assay, cells
were plated into 96-multiwell plates (Greiner) at di¡erent densities
(HT-29: 2U103 cells/well; LS513 and Co-115: 5U103 cells/well). Con-
ditioned media were diluted 1:2 in the respective culture media with
reduced serum concentrations (¢nal concentration: 1% FCS). Cells
were maintained in a total volume of 200 Wl for 5 days.
2.6. Cell proliferation assay
Proliferation was assessed in DMEM medium containing 0.5% FCS
(assay medium). Cell monolayers were washed with PBS, trypsinized
(0.05% trypsin/0.02% EDTA), pelleted, resuspended in assay medium
and distributed at 2U104 cells/well into 96-well £at-bottomed micro-
titer plates (Nunc, Wiesbaden-Biebrich, Germany), in the presence or
absence of recombinant IGF-I, -II or Long R3 IGF-I (Mediagnost,
Tuºbingen, Germany) at concentrations between 0 and 300 ng/ml in a
¢nal volume of 200 Wl. After ¢ve days cell proliferation was assessed,
based on the conversion of thiazolyl blue (MTT) into blue formazan
as described previously [20]. The measurements were carried out in
triplicates. Statistical analysis was performed using Student’s t-test.
2.7. Methylcellulose assay
Anchorage-independent growth was examined in a methylcellulose-
based clonogenic assay [21]. In brief, 103 cells were suspended in
medium containing 10% FCS, 20% conditioned media from parental
293 cells (293-0) and from the IGFBP-2 secreting cell clone 293-10
and 0.9% methylcellulose (Fluka, Deisenhofen, Germany) and plated
into 35 mm bacteriological Petri dishes (Greiner). As a control serum-
free medium was used instead of cell conditioned medium. Cells were
incubated at 37‡C and 5% CO2 for 1 week. Colonies of more than 50
cells were counted under an inverted microscope. All samples were set
up in triplicate.
3. Results
3.1. Transfected 293-cells express IGFBP-2 mRNA and
produce biologically active IGFBP-2
Genomic integration of the pCMV-int-mIGFBP-2 vector
was demonstrated by Southern blot hybridization in 10 of
16 clones analyzed (not shown). In the positive clones a 1.5
kb band was detected after EcoRI/PstI digestion as expected.
The endogenous IGFBP-2 gene was detected as a signal of
5 kb (not shown).
The positive clones expressed various levels of IGFBP-2
mRNA as demonstrated by Northern analysis (Fig. 2A).
Strong mRNA expression was found in clones 10 and 14,
intermediate expression was seen in clones 5 and 18. Low
mRNA expression was found in clone 13, whereas no expres-
sion was seen in clones 4 and 11 as well as in untransfected
293 cells (0). The signal between the 1.3 kb and the 2.4 kb
molecular weight standard bands corresponds to the length of
the endogenous mRNA transcript from mouse liver RNA (1.7
kb).
Quantitation of IGFBP-2 levels in the media conditioned by
clones 4, 13, 11, 5, 14 and 10 using a speci¢c radioimmuno-
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Fig. 1. Schematic representation of pCMV-int-mIGFBP-2. The con-
struct was cloned as described in Section 2. The XhoI-digested con-
struct used for the transfection includes the 680 bp CMV promoter,
120 bp rat insulin II intron A sequences, the 1450 bp mouse
IGFBP-2 cDNA, and 420 bp of the terminating sequences of the
human growth hormone gene.
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assay revealed concentrations of 0, 13, 61, 79, 180 and 489 ng/
ml per day, respectively. Western blot analysis using an anti-
serum speci¢c for IGFBP-2 detected a single band of the ex-
pected size (34 kDa) in conditioned media from clones 5, 10,
and 14 under reducing conditions (Fig. 2B). The capacity of
IGFBP-2 to bind IGF-II was shown by ligand blot analysis
using [125I]IGF-II (Fig. 2C). IGF-II binding was strong in
media of clones 10 and 14, intermediate in those from clones
5 and 13, and low or absent in media from clones 4 and 11.
Under non-reducing conditions, IGFBP-2 appeared as a dou-
ble band in the range of 32 kDa.
3.2. Growth activity of selected clones
In medium containing 0.5% or 1% FCS, proliferation of
293 clones secreting high amounts of IGFBP-2 was signi¢-
cantly reduced (P6 0.001) in the absence of exogenous
growth factors (Fig. 3A) when compared to 293 clones with
low IGFBP-2 production or the parental cells (293-0). This
reduction was completely reverted upon addition of exoge-
nous IGF-I or IGF-II. Representative dose-response curves
for two clones secreting high or low amounts of IGFBP-2
are shown in Fig. 3B. By contrast Long R3 IGF-I, an IGF-
I analogue with no a⁄nity for the IGFBPs [22], stimulated
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Fig. 3. A: Decreased proliferative activity in 293 clones with in-
creased IGFBP-2 secretion. Selected 293 clones were kept in di¡er-
ent concentrations of FCS for 5 days and analyzed for their prolif-
erative activity as described in Section 2. Measurements were
carried out in triplicate. The experiment was performed twice and a
representative set of data is given. B: Decreased proliferative activ-
ity in 293-14 cells is reconstituted by the addition of exogenous
IGF-I. Cells were kept in the presence or absence of IGF-I in 0.5%
FCS containing culture medium for 5 days and assayed as described
in Section 2. Measurements were carried out in triplicate. The ex-
periment was performed twice and a representative set of data is
given. C: Stimulation of proliferative activity in 293-10 cells using
rhIGF-I and Long R3 IGF-I. Cells were kept in the presence of
various IGF-I concentrations in 0.5% FCS containing culture me-
dium for 5 days and assayed as described in Section 2. Measure-
ments were carried out in triplicate.
Fig. 2. A: Expression of mIGFBP-2 mRNA in selected clones of
293 cells demonstrated by Northern blot hybridization. The rate of
expression exceeds the positive control (mouse liver) by severalfold.
No signal was found in Caco-2 cells which are known to express
only very small amounts of IGFBP-2 (exposure time: 3 min). B:
Identi¢cation of IGFBP-2 in the 293 cell conditioned media by
Western blot analysis. mIGFBP-2 was detected as described in Sec-
tion 2 using rabbit anti-hIGFBP-2 antiserum which is known to
crossreact with mouse IGFBP-2. C: Secretion of IGFBP-2 into con-
ditioned media by selected 293 clones shown by Ligand blot analy-
sis. Cells were washed two times and kept serum-free for 24 h.
Equal amounts of cell conditioned media were analyzed as described
in Section 2.
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proliferative activity of IGFBP-2 secreting 293 cell clone 10 at
10-fold lower concentrations when compared to rhIGF-I (Fig.
3C). Identical results were obtained in 293-5 cells, whereas no
discriminatory e¡ect of rhIGF-I and long R3 IGF-I was ob-
served in controls or in the parental cell line (not shown).
3.3. IGFBP-2 inhibits proliferation of IGF-responsive colon
carcinoma cell lines
To demonstrate e¡ects of media conditioned by the selected
293 clones, several colon carcinoma cell lines were exposed to
these media containing IGFBP-2 at concentrations between
13 ng/ml and 489 ng/ml in the presence or absence of exoge-
nous IGF-II (50 ng/ml). In LS513 (Fig. 4A) and HT-29 (Fig.
4B) colon carcinoma cells media conditioned by clones 10, 14
and 13 signi¢cantly reduced proliferative activity when com-
pared to media conditioned by controls (clone 11 and 0 which
represents parental 293 cells). However, when the conditioned
media were supplemented with exogenous IGF-II (50 ng/ml)
the negative e¡ects were reverted dependent on the IGFBP-2
concentration. The negative e¡ects exerted by the di¡erent
conditioned media were reverted partially for clones 10 and
14 and were reverted completely for clone 13. Moreover, IGF-
II at 50 ng/ml was su⁄cient to signi¢cantly increase prolifer-
ation of HT-29 and LS513 cells when exposed to media con-
ditioned by clone 11 and parental 293 cells (0). No e¡ect of
either IGFBP-2 or IGF-II was observed on growth activity of
IGF-unresponsive Co-115 cells (Fig. 4C).
3.4. Anchorage-independent growth is inhibited in HT-29 and
LS513 colon carcinoma cells
Anchorage-independent colony formation re£ects the tu-
morigenic potential of the cell [23]. Therefore we investigated
the e¡ects of media conditioned by two di¡erent selected 293
cell clones containing high (293-10: 489 ng/ml) or undetect-
able (293 parental cells) amounts of IGFBP-2 (Fig. 5). Start-
ing with 103 LS513 colon carcinoma cells after 1 week
240 þ 16 colonies were counted (24% cloning e⁄ciency). Col-
ony formation (112 þ 11) was inhibited by 50% when cells
were coincubated in medium containing high amounts of
IGFBP-2, but no signi¢cant inhibition was measured when
coincubated with parental 293 cell conditioned medium
(220 þ 15 colonies). Similar results were obtained in HT-29
colon carcinoma cells, which is known not to express
IGFBP-2 [24]. Cloning e⁄ciency was 27.3% when no condi-
tioned medium was present during the assay. After coincuba-
tion in high IGFBP-2 concentrations containing media colony
formation was signi¢cant decreased by 23% (241 þ 6) if com-
pared to medium conditioned by parental 293 cells (313 þ 5).
No signi¢cant di¡erence was measured in both cell lines if
medium conditioned by untransfected 293-0 cells was com-
pared with serum-free control medium.
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Fig. 5. mIGFBP-2 inhibits anchorage-independent growth of LS513
and HT-29 colon carcinoma cells in methylcellulose. 103 cells were
seeded in triplicate in the presence of conditioned medium (20%)
containing high (293-10) or undetectable (293-0) amounts of
mIGFBP-2. As a control serum-free medium was used. Colonies of
more than 50 cells were counted after 1 week. Values are means of
triplicates þ S.D. and representent one of three (LS513) or two (HT-
29) independent experiments. Di¡erent superscripts indicate signi¢-
cant di¡erences (P6 0.01).
Fig. 4. E¡ects of media conditioned by selected 293 cell clones on
proliferative activity of di¡erent colon carcinoma cell lines in the
absence (¢lled bars) or presence (open bars) of exogenous IGF-II.
Two IGF-responsive colon carcinoma cell lines (A: LS513; B: HT-
29) and one IGF-unresponsive cell line (C: Co115) were analyzed.
The cells were kept for 5 days before the proliferation assays were
performed as described in Section 2. At the bottom of the ¢gure the
293 clone number used for the preparation of the conditioned me-
dium as well as the respective IGFBP-2 concentration is indicated.
Di¡erent superscripts indicate signi¢cant (P6 0.01) di¡erences.
Measurements were carried out in triplicate. The ¢gure shows repre-
sentative sets of data of at least two experiments.
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4. Discussion
IGFBP-2 is known to be upregulated in di¡erent patholog-
ical or unphysiological situations like trauma [25,26], certain
tumors [5,27^30] or during starvation [3]. However, the func-
tion of IGFBP-2 remains unclear so far, since di¡erent in
vitro studies concerning the biological e¡ects of IGFBP-2
have led to contradictory assumptions and results. Either neg-
ative [31^34] or positive e¡ects [35,36] have been observed
upon administration of IGFBP-2 in di¡erent cell systems.
The ¢ndings that retinoic acid- [37^39] or dexamethasone-
[40] mediated growth inhibition is accompanied by increased
IGFBP-2 expression and that speci¢c IGFBP-2 proteolysis
results in reduced a⁄nity for IGF-II [39] suggest negative
growth regulation. Furthermore, increased proliferation has
been demonstrated in stably transfected IEC cells by use of
an IGFBP-2 antisense construct [41]. But it also has been
concluded from several in vitro studies [42^45], where
IGFBP-2 expression correlated positively with a proliferative
state of the cells, that IGFBP-2 might be an inducer of cell
growth rather than an inhibitor. According to these studies
synergistic mechanisms have been postulated between IGFBP-
2 and the IGFs. In addition in osteosarcoma cells even IGF
independent growth stimulation has been suggested for
IGFBP-2 [36].
To determine potential e¡ects of IGFBP-2 overproduction
in a de¢ned cell culture model we stably transfected 293 cells.
The transfection resulted in the establishment of di¡erent cell
clones with various levels of IGFBP-2 overexpression. To de-
¢ne the e¡ect of IGFBP-2 overproduced in vitro, we analyzed
the di¡erent clones and measured the e¡ects of conditioned
media derived from IGFBP-2 secreting 293 cells also in di¡er-
ent tumor cell lines. Transfected 293 cells were identi¢ed by
the presence of a restriction enzyme genomic DNA fragment
(1.5 kb) in accordance with the restriction map from the ex-
pression construct. All positive clones expressed an mRNA
transcript of about 1.7 kb, matching the length of the endog-
enous IGFBP-2 gene product from mouse liver.
Transfected 293 cells secreted various amounts of biologi-
cally active IGFBP-2 as demonstrated by Western ligand and
immunoblotting. Two bands appeared under non-reducing
conditions, both of which were able to bind IGF-II and
both were recognized by a speci¢c antiserum (not shown).
Two bands (33 kDa and 37 kDa) representing IGFBP-2
have also been demonstrated by others [46]. Using reducing
SDS-PAGE, only one band was detected, indicating the pres-
ence of two IGFBP-2 isoforms.
IGFBP-2 signi¢cantly reduced proliferation of stably trans-
fected 293 cells. Furthermore, the negative e¡ects were com-
pletely abolished upon the addition of exogenous IGF-I (or
IGF-II; not shown) at high concentrations and Long R3 IGF-
I in lower concentrations when compared to rhIGF-I. In two
IGF-responsive colon cancer cell line (HT-29 cells and LS513
cells) conditioned media from IGFBP-2 secreting 293 cells,
negative e¡ects on proliferation were con¢rmed and similarly
compensated by the administration of exogenous IGFs. More-
over, IGFBP-2 negatively in£uenced the capacity of two colon
carcinoma cell lines to form colonies under anchorage-inde-
pendent growth conditions in methylcellulose. Most interest-
ingly, the extent of inhibition exerted by IGFBP-2 correlates
with inhibition of proliferation and colony formation by KIR3
in the two colon carcinoma cell lines [47]. This suggests that
IGFBP-2 might also impair the tumorigenicity of these cells in
vivo. Taken together the ¢ndings indicate that mIGFBP-2
may act by interfering with the interaction between the
IGFs and their receptors and thereby prevent the transmission
of their mitogenic signals. Thus, under di¡erent levels of
IGFBP-2 overproduction, no IGF-independent e¡ects could
be observed. IGFBP-2 was detected on the cell surface of
colorectal cancers [27], and it was further demonstrated that
binding occurs to heparin and proteoglycans [48,49]. How-
ever, the biological consequences of membrane attachment
remain to be elucidated. As a potential positive mechanism
it might be speculated that membrane associated IGFBP-2
concentrates the IGFs in close vicinity of their receptors
and thereby increases their mitogenic potential. In the di¡er-
ent positive clones membrane association of IGFBP-2 was
demonstrated in crosslinking experiments using puri¢ed
membranes whereas no IGFBP-2 association was found in
negative clones (data not shown). However, the fact that
Long R3 IGF-I, which does not interact with IGFBP-2 [22],
was more potent in stimulating cell proliferation when com-
pared with rhIGF-I argues strongly against IGFBP-2-medi-
ated positive signals in our cell culture model. In addition,
it has been shown that both soluble and membrane-associated
IGFBP-2 competes with IGF receptors for the IGFs [33].
Neither IGFBP-2 containing conditioned media, nor the ad-
ministration of IGFs were able to modulate proliferation in
Co115 cells. Co115 cells are known to be IGF-unresponsive
since administration of exogenous IGFs does not lead to
IRS-1 phosphorylation despite IGF-I receptor expression
[50].
In mice divergently selected for high or low 8-week body
weight, serum levels of IGFBP-2 were also clearly increased in
the low and decreased in the high weight mouse line, when
compared to randomly bred mice [18], which also points to a
negative e¡ect on growth. Furthermore, increased IGFBP-2
expression was observed in the mammary glands of IGF-I
transgenic rabbits [15]. Revealing IGFBP-2 as a negative
growth factor in vitro, increased expression in these models
might be interpreted as an antagonistic response of the IGF
system to high IGF concentrations in order to prevent major
pathological e¡ects. In 293 cells IGFBP-2 regulation by IGF-
I, -II and insulin [51] was demonstrated. According to the
strong growth inhibitory potential of IGFBP-2, increased
IGFBP-2 levels upon the addition of exogenous IGF-I, -II
or insulin in 293 cells point to an antagonistic function in
293 cells. Moreover, the very common observation of in-
creased IGFBP-2 levels in conditioned media from di¡erent
tumor cell lines, which had led to the assumption that IGFBP-
2 represents a positive growth factor (see above), might thus
be interpreted in the same way as an autocrine response of the
IGF system against high proliferation in vitro.
In summary, mIGFBP-2 displayed negative growth e¡ects
in all IGF-responsive cell lines investigated. The negative ef-
fects were abolished by the addition of exogenous IGFs. It is
concluded from our data that IGFBP-2 represents an impor-
tant inhibitor of cell proliferation in 293 cells and di¡erent
IGF-responsive colon carcinoma cell lines.
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